Influenza Vaccines – Pipeline Assessment And Market Forecasts To 2017-sweets parade

Health GlobalData estimated the global influenza vaccines market to be worth $2.8 billion in 2009. It is forecast to grow at a CAGR of 8% to reach $5 billion by 2017. This high growth forecast is primarily attributed to an increase in the patient population as a result of the increasing world population, and the need to get vaccinated each year. This growth will be further supported by increased production capacities of companies to cater to the rising demand. The strong product pipeline will complement the existing products by providing effective treatment options. GlobalData found that the products currently in the market are highly efficacious in providing protection against the disease with minimum side-effects. All the marketed products provide high seroprotection rates and seroconversion rates against the disease. The key products such as Fluzone, Fluvirin, Fluarix, FluLaval and Flumist are able to satisfy the demand in the influenza vaccines market. The unmet need arises from the fact that vaccination against one strain of the virus may not provide protection against other strains of the influenza virus. More importantly, the virus strains change every year, and so people have to get themselves vaccinated each year. For further details, please click or add the below link to your browser: The influenza vaccines market has very low unmet needs as the market is very well served by the current product options. This leaves little scope for new entrants to capture value from under-served segments. The new products have to aim at getting market share by providing unique offerings and targeting niche segments. The likely under-served segments are elderly populations and people allergic to egg-based vaccines. The current pipeline, however, is strong enough to cater to this unmet need. GlobalData found that the product pipeline for influenza vaccines is strong with 93 molecules in various phases of clinical development. There are seven molecules in Phase III, 27 in Phase II and 26 molecules undergoing Phase I clinical trials. These vaccines are as safe and efficacious as the currently marketed ones with novel development procedure or routes of administration. They target the small unmet need that exists in the market. They will compete with the well established marketed vaccines and are likely to redefine the competitive landscape in the market. GlobalData, the industry analysis specialist, has released its new report, Influenza Vaccines – Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Influenza Vaccines market. The report identifies the key trends shaping and driving the global Influenza Vaccines market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Influenza Vaccines sector. For further details, please click or add the below link to your browser: Visit our report store: For more details contact: [email protected] North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782 About the Author: GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. Article Published On: ..articlesnatch.. – Health 相关的主题文章: